Abstract

Membrane proteins are important drug targets yet are notoriously difficult to work with. Our proprietary approach, Salipro DirectMX, incorporates membrane proteins directly from cells into lipid Salipro® nanoparticles. Salipro DirectMX presents new opportunities for de novo development and characterization of biologics and small molecule drugs. We will present our latest developments and showcase how native GPCRs and ion channels can be reconstituted into Salipro nanoparticles, enabling the discovery of novel therapeutics.